Greg A. Knock

Greg A. Knock

Auto-generated profile, based on publicly available information

Greg A. Knock

School of Bioscience Education, Faculty of Life Sciences and Medicine, King's College London, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2009 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
GKGreg A. Knock
Greg A. Knock
VSVladimir A. Snetkov
Vladimir A. Snetkov
YSYasin Shaifta
Yasin Shaifta
MCMichelle Connolly
Michelle Connolly
SDSvetlana Drndarski
Svetlana Drndarski
JWJeremy P.T. Ward
Jeremy P.T. Ward

15 September 2011 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
GKGreg A. Knock
Greg A. Knock
JWJeremy P.T. Ward
Jeremy P.T. Ward
Reactive oxygen species (ROS) are continuously generated in vascular tissues by various oxidoreductase enzymes. They contribute to normal cell signaling, and modulate vascular smooth muscle tone and endothelial permeability in response to physiological agonists and to various cellular stresses and environmental factors, such as hypoxia. While concentrations of ROS are normally tightly controlled by cellular redox buffer systems, if produced in excess they may contribute to vascular disease. Protein kinases are essential components of most cell signaling pathways, including those involving ROS. The functioning of several members of this highly diverse group of enzymes, which include receptor and nonreceptor tyrosine kinases, protein kinase C, mitogen-activated kinases, and Rho-kinase, are modified by ROS, either through direct oxidative modification or indirectly through modification of associated proteins such as tyrosine phosphatases and monomeric G proteins. In this review, we discuss the molecular mechanisms of redox modification of these proteins, the downstream pathways affected, the often complex interaction between major kinase pathways, and feedback to ROS production itself. We also discuss complicating factors such as differential actions of superoxide anion and hydrogen peroxide, questions concerning concentration dependence, and the significance of signaling microdomains. Antioxid. Redox Signal. 15, 1531–1547.

1 December 2014 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
CMCharles E. MacKay
Charles E. MacKay
GKGreg A. Knock
Greg A. Knock
Reactive oxygen species (ROS) are now recognised as second messenger molecules that regulate cellular function by reversibly oxidising specific amino acid residues of key target proteins. Amongst these are the Src‐family kinases (SrcFKs), a multi‐functional group of non‐receptor tyrosine kinases highly expressed in vascular smooth muscle (VSM). In this review we examine the evidence supporting a role for ROS‐induced SrcFK activity in normal VSM contractile function and in vascular remodelling in cardiovascular disease. VSM contractile responses to G‐protein‐coupled receptor stimulation, as well as hypoxia in pulmonary artery, are shown to be dependent on both ROS and SrcFK activity. Specific phosphorylation targets are identified amongst those that alter intracellular Ca2+ concentration, including transient receptor potential channels, voltage‐gated Ca2+ channels and various types of K+ channels, as well as amongst those that regulate actin cytoskeleton dynamics and myosin phosphatase activity, including focal adhesion kinase, protein tyrosine kinase‐2, Janus kinase, other focal adhesion‐associated proteins, and Rho guanine nucleotide exchange factors. We also examine a growing weight of evidence in favour of a key role for SrcFKs in multiple pro‐proliferative and anti‐apoptotic signalling pathways relating to oxidative stress and vascular remodelling, with a particular focus on pulmonary hypertension, including growth‐factor receptor transactivation and downstream signalling, hypoxia‐inducible factors, positive feedback between SrcFK and STAT3 signalling and positive feedback between SrcFK and NADPH oxidase dependent ROS production. We also discuss evidence for and against the potential therapeutic targeting of SrcFKs in the treatment of pulmonary hypertension.

1 December 2004 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JWJeremy Ward
Jeremy Ward
GKGreg A. Knock
Greg A. Knock
VSVladimir A. Snetkov
Vladimir A. Snetkov
PAPhilip Aaronson
Philip Aaronson

1 November 2008 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
GPGhazaleh Esmaeil Pourmahram
Ghazaleh Esmaeil Pourmahram
VSVladimir A. Snetkov
Vladimir A. Snetkov
YSYasin Shaifta
Yasin Shaifta
SDSvetlana Drndarski
Svetlana Drndarski
GKGreg A. Knock
Greg A. Knock
JWJeremy Ward
Jeremy Ward